Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 1, 2006, Pages 182-188

  Szapary, Philippe O ^a,b,c   Bloedon, LeAnne T ^a,b   Samaha, Frederick F ^a   Duffy, Danielle ^e   Wolfe, Megan L ^b   Soffer, Daniel ^e   Reilly, Muredach P ^a   Chittams, Jesse ^a   Rader, Daniel J ^b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PFIZER INC   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e NONE

Author keywords

Atherosclerosis; Inflammation; Lipids; Lipoproteins; Metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; PARTICLE SIZE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; ATHEROSCLEROSIS; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADIPONECTIN; ADULT; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 33644826717     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000195790.24531.4f     Document Type: Article

References (33)

1. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the Am Heart Association/National Heart, Lung, and Blood Institute/Am Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-556.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
3. Kahn R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304.
4. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
5. Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J. 2004;148:211-221.
6. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-2104.
7. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
9. Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, Usadel KH, Konrad T. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2002;87:5503-5506.
10. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K. antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493-2499.
11. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180.
12. Festa A, Williams K, Hanley AJG, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation. 2005;111:3465-3472.
13. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 2000;278:704-711.
14. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323-1332.
15. Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003;52:652-657.
16. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-1737.
17. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol. 2005;25:2185-2191.
18. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, for the GLAI Study Investigators. A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554.
19. Guerrero-Romero F, Rodriguez-Moran M. Pioglitazone increases serum magnesium levels in glucose-intolerant subjects. A randomized, controlled trial. Exp Clin Endocrinol Diabetes. 2003;111:91-96.
20. Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, Marz W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003;26:2588-2594.
21. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381-387.
22. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Effect of troglitazone on lipoprotein(a) levels in obese subjects. Diabetes Care. 1999;22:1752-1753.
23. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
24. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45:1925-1931.
25. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362-365.
26. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA. 2004;292:1365-1367.
27. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-2974.
28. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932-939.
29. Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, Kim SY, Lee HK, Park KS. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism. 2005;54:314-320.
30. Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol. 2003;1:384-387.
31. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes. 2005;54:1150-1156.
32. Raji A, Seely EW, Bekins SA, Williams growthhormone (GH), Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26:172-178.
33. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47:1519-1527.